123 related articles for article (PubMed ID: 29681014)
1. Toxicity and quality of life in published clinical trials for advanced lung cancer.
Zwitter M
Support Care Cancer; 2018 Oct; 26(10):3453-3459. PubMed ID: 29681014
[TBL] [Abstract][Full Text] [Related]
2. Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Sztankay M; Giesinger JM; Zabernigg A; Krempler E; Pall G; Hilbe W; Burghuber O; Hochmair M; Rumpold G; Doering S; Holzner B
BMC Cancer; 2017 Aug; 17(1):565. PubMed ID: 28835219
[TBL] [Abstract][Full Text] [Related]
3. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
4. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
[TBL] [Abstract][Full Text] [Related]
5. Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.
Hollen PJ; Gralla RJ; Rittenberg CN
Support Care Cancer; 2004 Nov; 12(11):767-73. PubMed ID: 15206013
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials.
Mandrekar SJ; Northfelt DW; Schild SE; Foster NR; Bot B; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Adjei AA; Jett JR
J Thorac Oncol; 2006 Jul; 1(6):556-63. PubMed ID: 17409917
[TBL] [Abstract][Full Text] [Related]
9. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer.
Mohan A; Singh P; Kumar S; Mohan C; Pathak AK; Pandey RM; Guleria R
Asian Pac J Cancer Prev; 2008; 9(4):557-62. PubMed ID: 19256738
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer.
Li L; Huang XE
Asian Pac J Cancer Prev; 2016; 17(5):2583-5. PubMed ID: 27268634
[TBL] [Abstract][Full Text] [Related]
11. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
12. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
13. Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy.
Gralla RJ; Thatcher N
Lung Cancer; 2004 Dec; 46 Suppl 2():S41-7. PubMed ID: 15698531
[TBL] [Abstract][Full Text] [Related]
14. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Bezjak A; Lee CW; Ding K; Brundage M; Winton T; Graham B; Whitehead M; Johnson DH; Livingston RB; Seymour L; Shepherd FA
J Clin Oncol; 2008 Nov; 26(31):5052-9. PubMed ID: 18809617
[TBL] [Abstract][Full Text] [Related]
16. Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
SjØgren K; Jacobsen KA; GrØnberg BH; Halvorsen TO
Anticancer Res; 2020 Nov; 40(11):6399-6406. PubMed ID: 33109578
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.
Kelsey CR; Das S; Gu L; Dunphy FR; Ready NE; Marks LB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):997-1004. PubMed ID: 26581138
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up.
Yang SC; Kuo CW; Lai WW; Lin CC; Su WC; Chang SM; Wang JD
J Thorac Oncol; 2019 Nov; 14(11):1892-1900. PubMed ID: 31352073
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
Gebbia V; Gridelli C; Verusio C; Frontini L; Aitini E; Daniele B; Gamucci T; Mancuso G; Di Maio M; Gallo C; Perrone F; Morabito A
Lung Cancer; 2009 Feb; 63(2):251-8. PubMed ID: 18632181
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
